Last reviewed · How we verify
Taractan (CHLORPROTHIXENE)
Taractan (chlorprothixene) is a small molecule drug developed by Roche, targeting the 5-hydroxytryptamine receptor 2A. It is a chlorprothixene class medication, approved by the FDA in 1967 for the treatment of schizophrenia. As an off-patent medication, there are no active generic manufacturers. Key safety considerations include its 25.8-hour half-life and 41% bioavailability. Taractan is currently owned by Roche.
At a glance
| Generic name | CHLORPROTHIXENE |
|---|---|
| Sponsor | Roche |
| Drug class | chlorprothixene |
| Target | 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1967 |
Approved indications
- Schizophrenia
Common side effects
Drug interactions
- cisapride
Key clinical trials
- Bariatric Surgery and Pharmacokinetics of Chlorprothixene
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Antipsychotics and Risk of Hyperglycemic Emergencies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taractan CI brief — competitive landscape report
- Taractan updates RSS · CI watch RSS
- Roche portfolio CI